CY1120835T1 - Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων - Google Patents

Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων

Info

Publication number
CY1120835T1
CY1120835T1 CY181101065T CY181101065T CY1120835T1 CY 1120835 T1 CY1120835 T1 CY 1120835T1 CY 181101065 T CY181101065 T CY 181101065T CY 181101065 T CY181101065 T CY 181101065T CY 1120835 T1 CY1120835 T1 CY 1120835T1
Authority
CY
Cyprus
Prior art keywords
disorders
ursodeoxychologic
neurodegystanic
tudca
taurus
Prior art date
Application number
CY181101065T
Other languages
English (en)
Inventor
Gilberto Rinaldi
Original Assignee
Bruschettini Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48949193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bruschettini Srl filed Critical Bruschettini Srl
Publication of CY1120835T1 publication Critical patent/CY1120835T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτεται μια μέθοδος για τη θεραπεία νευροεκφυλιστικών διαταραχών, όπως της ALS, της ασθένειας Alzheimer, της ασθένειας Parkinson, της ασθένειας Huntington και/ή της μελαχρωστικής αμφιβληστοειδοπάθειας, η οποία μέθοδος περιλαμβάνει χορήγηση σε έναν ασθενή ταυρο-ουρσοδεοξυχολικού οξέος ή ενός φαρμακευτικώς αποδεκτού άλατος αυτού.
CY181101065T 2013-07-01 2018-10-17 Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων CY1120835T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055383 WO2015001379A1 (en) 2013-07-01 2013-07-01 Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
CY1120835T1 true CY1120835T1 (el) 2019-12-11

Family

ID=48949193

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101065T CY1120835T1 (el) 2013-07-01 2018-10-17 Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων

Country Status (15)

Country Link
EP (1) EP3016654B1 (el)
CN (2) CN105358147A (el)
CY (1) CY1120835T1 (el)
DK (1) DK3016654T3 (el)
ES (1) ES2691408T3 (el)
HR (1) HRP20181554T1 (el)
HU (1) HUE040027T2 (el)
LT (1) LT3016654T (el)
PL (1) PL3016654T3 (el)
PT (1) PT3016654T (el)
RS (1) RS57763B1 (el)
RU (1) RU2016102092A (el)
SI (1) SI3016654T1 (el)
TR (1) TR201815345T4 (el)
WO (1) WO2015001379A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2023507153A (ja) * 2019-12-16 2023-02-21 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 筋萎縮性側索硬化症及び関連する疾患の治療
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
JP2023518670A (ja) * 2020-02-13 2023-05-08 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
CN112972480A (zh) * 2021-03-09 2021-06-18 兆科药业（广州）有限公司 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230767A1 (en) * 2003-04-02 2004-11-23 Regents Of The University Of Minnesota Methods of promoting cell viability
CA2581126A1 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
ES2358089T3 (es) * 2004-11-01 2011-05-05 Seo Hong Yoo Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica.
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
EP1871385A1 (en) 2005-02-10 2008-01-02 Regents Of The University Of Minnesota Methods for treating visual disorders
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
EP2422787A1 (en) 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)

Also Published As

Publication number Publication date
RU2016102092A (ru) 2017-08-04
SI3016654T1 (sl) 2019-05-31
HRP20181554T1 (hr) 2018-12-14
PT3016654T (pt) 2018-11-09
EP3016654B1 (en) 2018-09-05
ES2691408T3 (es) 2018-11-27
HUE040027T2 (hu) 2019-02-28
DK3016654T3 (en) 2018-11-05
EP3016654A1 (en) 2016-05-11
LT3016654T (lt) 2018-11-12
CN105358147A (zh) 2016-02-24
TR201815345T4 (tr) 2018-11-21
CN109999030A (zh) 2019-07-12
RS57763B1 (sr) 2018-12-31
PL3016654T3 (pl) 2019-02-28
WO2015001379A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
CY1120835T1 (el) Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1125058T1 (el) Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CY1124568T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
IL247085A0 (en) Methods for treating Alzheimer's disease
IL246999A0 (en) Methods for treating Alzheimer's disease
DK3347002T3 (da) Behandling af alzheimers sygdom i en bestemt patientpopulation
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
CY1122640T1 (el) Θεραπεια και προφυλαξη δερματιτιδας ακτινοβολιας
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas